Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haelan 951 is a fermented soy beverage developed by Haelan Products and studied by the M.D. Anderson Cancer Center for the management of cancer-associated anorexia and cachexia. Classified as a nutritional supplement or nutraceutical, it is produced through a specialized fermentation process that concentrates the nutrients of approximately 25 pounds of soybeans into a single 8-ounce bottle. The product contains a complex mixture of active ingredients, including high concentrations of soy isoflavones (genistein, daidzein, and glycitein), soy proteins, protease inhibitors, saponins, phytosterols, and essential minerals like selenium and zinc. Its primary biological mechanism involves the inhibition of nuclear factor-kappa B (NF-kB) by isoflavones, which is thought to modulate inflammatory pathways that contribute to weight loss and appetite suppression in cancer patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Haelan 951.